Latest News

Englumafusp Alfa/Glofitamab Combo Delivers Early Responses in Patients with NHL
Englumafusp Alfa/Glofitamab Combo Delivers Early Responses in Patients with NHL

July 7th 2024

The combination of englumafusp alfa and glofitamab showed a BOR of 67.0% and CR rate of 57.0% in second-line settings. In third-line settings, the BOR was 65.7% and the CR rate was 52.8%.

New APL Treatment Shows Promise: Higher Survival Rates, Less Toxicity
New APL Treatment Shows Promise: Higher Survival Rates, Less Toxicity

July 6th 2024

Rhodes Evaluates Toxicity Concerns With ABVD  and Brentuximab Vedotin in cHL
Rhodes Evaluates Toxicity Concerns With ABVD and Brentuximab Vedotin in cHL

June 29th 2024

Different Options Discussed for DLBCL in Later-Lines of Treatment
Different Options Discussed for DLBCL in Later-Lines of Treatment

June 13th 2024

Early Data Shows Axi-Cel’s Potential in Treating R/R Primary and Secondary CNS Lymphomas
Early Data Shows Axi-Cel’s Potential in Treating R/R Primary and Secondary CNS Lymphomas

June 13th 2024